Dan Marshall

Dan Marshall has 20+ years of experience in drug discovery as a medicinal chemist. Dan began their career as an Assistant Research Scientist I/II at Bristol-Myers Squibb in 1991, where they prepared Paclitaxel intermediates and analogs for antitumor screening, focusing on pro-drug development and MDR issues, enediyne intermediates and analogs for biological evaluation as antitumor agents, and pyrimidinobenzodiazapine analogs for biological evaluation as CNS anti-stroke agents. In 1999, they moved to Boehringer Ingelheim Pharmaceuticals as a Principal Scientist and Senior Scientist, where they developed a keen understanding of the concepts, processes and strategies which lead to successful discovery efforts, and gained experience in NCE modulation of multiple target classes (kinase, GPCR, CYP450, NHR, pseudokinase and synthase) with an expertise in inflammation, immunity and cardiometabolic therapeutic areas (Indications: SSc, Crohn's Disease, UC, RA, MS, DN, IPF, hypertension, atherosclerosis, oncology). In 2017, Dan Marshall became the Director of Medicinal Chemistry at Cybrexa, where they built the chemistry program to design and synthesize novel peptide drug conjugates which targeted the acidic tumor micro-environment to selectively target cancer cells, deliver small molecule oncology agents and improve therapeutic safety/efficacy indices. Dan also developed an efficient in-house synthetic capability and managed external CRO resources to best meet the needs of all aspects of conjugate synthesis. In 2019, they moved to ChemoCentryx (Acquired by Amgen) as the Director of Medicinal Chemistry. Currently, they are the Senior Director, Head of Medicinal Chemistry at Carmot Therapeutics, Inc.

Dan Marshall obtained a B.S. in Chemistry from Colorado State University from 1987 to 1991. Dan then went on to pursue a Ph.D. in Chemistry from Emory University from 1994 to 1999.